EyePoint Pharmaceuticals, Inc.
EYPT
$6.25
-$0.61-8.89%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -193.63% | -132.80% | -34.49% | -38.37% | 67.55% |
| Total Depreciation and Amortization | 316.96% | 254.78% | 174.24% | 188.57% | -66.57% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 96.13% | 55.15% | 85.41% | 332.07% | -87.72% |
| Change in Net Operating Assets | 91.06% | -148.45% | -95.68% | -1,109.45% | -352.53% |
| Cash from Operations | -55.13% | -156.70% | -135.39% | -85.16% | -83.58% |
| Capital Expenditure | 56.51% | 8.49% | -127.27% | -146.69% | -50.94% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -106.59% | -- | -1,250.51% | -32.45% | -238.10% |
| Cash from Investing | -103.53% | 1,041.63% | -1,291.02% | -35.16% | -243.23% |
| Total Debt Issued | -- | -- | -- | -- | -100.00% |
| Total Debt Repaid | -- | -- | -- | -- | 100.00% |
| Issuance of Common Stock | -30.40% | 11.76% | 12,400.00% | 1,738.71% | -- |
| Repurchase of Common Stock | -- | -- | -- | -2,477.51% | 100.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -913.89% | 100.00% | 83.85% | -- | -- |
| Cash from Financing | -30.57% | 14.78% | 100.90% | 102.25% | 376,798.28% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -86.59% | -66.70% | -632.76% | -201.16% | 631.23% |